Literature DB >> 1855015

Persistence of antibody after accelerated immunisation with diphtheria/tetanus/pertussis vaccine.

M E Ramsay1, M J Corbel, K Redhead, L A Ashworth, N T Begg.   

Abstract

OBJECTIVE: To determine the persistence of antibody to diphtheria, tetanus, and pertussis in children receiving an accelerated schedule of primary immunisation.
DESIGN: Controlled study of antibody testing of blood samples from children immunised according to various schedules: three doses of triple vaccine completed at 8-13 calendar months, 6-7 calendar months, before 6 calendar months, or three doses followed by diphtheria/tetanus before age 2.
SETTING: Plymouth Health Authority.
SUBJECTS: 129 children aged 4 years who had received three doses of diphtheria/tetanus/pertussis vaccine with or without a diphtheria/tetanus booster. MAIN OUTCOME MEASURES: Diphtheria and tetanus antitoxin concentrations and antibody titres to pertussis toxin, filamentous haemagglutinin, and agglutinogens 2 and 3.
RESULTS: All children had protective concentrations of antitoxin to diphtheria and tetanus (greater than or equal to 0.01 IU/ml). There was no evidence of a significant difference in diphtheria or tetanus antitoxin concentrations and pertussis antibody titres in children immunised with an accelerated course (third dose of triple vaccine before 6 months) compared with those who received a longer course (third dose at 8-13 months) with no booster (geometric mean antitoxin concentration 0.411 (95% confidence interval 0.273 to 0.618) v 0.426 (0.294 to 0.616) for diphtheria and 0.358 (0.231 to 0.556) v 0.299 (0.197 to 0.453) for tetanus; geometric mean antibody titres 903 (500 to 1631) v 1386 (848 to 2266) for pertussis filamentous haemagglutinin, 179 (130 to 248) v 232 (167 to 322) for pertussis toxin, and 2002 (1276 to 3142) v 3591 (2220 to 5809) for agglutinogens 2 and 3).
CONCLUSION: Immunisation with three doses of triple vaccine at monthly intervals completed before 6 months of age probably provides adequate protection against diphtheria, tetanus, and whooping cough which will persist until the age of the preschool booster.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1855015      PMCID: PMC1670210          DOI: 10.1136/bmj.302.6791.1489

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  7 in total

1.  Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens.

Authors:  E Miller; L A Ashworth; A Robinson; P A Waight; L I Irons
Journal:  Lancet       Date:  1991-01-12       Impact factor: 79.321

2.  Estimation of Corynebacterium diphtheriae antitoxin in human sera: a comparison of an enzyme-linked immunosorbent assay with the toxin neutralisation test.

Authors:  M Melville-Smith; A Balfour
Journal:  J Med Microbiol       Date:  1988-04       Impact factor: 2.472

3.  Durability of immunity to diphtheria, tetanus and poliomyelitis after a three dose immunization schedule completed in the first eight months of life.

Authors:  A E Jones; A Johns; D I Magrath; M Melville-Smith; F Sheffield
Journal:  Vaccine       Date:  1989-08       Impact factor: 3.641

4.  Evidence of whooping-cough-vaccine efficacy from the 1978 whooping-cough epidemic in Hertfordshire.

Authors:  M A Church
Journal:  Lancet       Date:  1979-07-28       Impact factor: 79.321

5.  A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera.

Authors:  M E Melville-Smith; V A Seagroatt; J T Watkins
Journal:  J Biol Stand       Date:  1983-04

Review 6.  The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age.

Authors:  N Halsey; A Galazka
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

7.  Reactions and antibody responses to reinforcing doses of adsorbed and plain tetanus vaccines.

Authors:  L H Collier; S Polakoff; J Mortimer
Journal:  Lancet       Date:  1979-06-30       Impact factor: 79.321

  7 in total
  11 in total

1.  Technical and diagnostic performance of five commercial anti-diphtheria toxoid IgG enzyme-linked immunosorbent assay kits.

Authors:  A Faruq; L Dadson; H Cox; F Alcock; A R Parker
Journal:  Clin Vaccine Immunol       Date:  2010-08-25

2.  Accelerated immunisation with diphtheria-tetanus-pertussis vaccine.

Authors:  M Ramsay; N Begg; M J Corbel
Journal:  BMJ       Date:  1991-09-14

3.  Accelerated immunisation with diphtheria-tetanus-pertussis vaccine.

Authors:  N W Preston
Journal:  BMJ       Date:  1991-07-27

4.  Comparison of five commercial anti-tetanus toxoid immunoglobulin G enzyme-linked immunosorbent assays.

Authors:  A L Perry; A J Hayes; H A Cox; F Alcock; A R Parker
Journal:  Clin Vaccine Immunol       Date:  2009-09-30

5.  Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines.

Authors:  Dawn B Beaulieu; Ashwin N Ananthakrishnan; Christopher Martin; Russell D Cohen; Sunanda V Kane; Uma Mahadevan
Journal:  Clin Gastroenterol Hepatol       Date:  2017-09-01       Impact factor: 11.382

6.  Age-specific efficacy of pertussis vaccine during epidemic and non-epidemic periods.

Authors:  M E Ramsay; C P Farrington; E Miller
Journal:  Epidemiol Infect       Date:  1993-08       Impact factor: 2.451

7.  Antibody response to accelerated Hib immunisation in preterm infants receiving dexamethasone for chronic lung disease.

Authors:  M J Robinson; F Campbell; P Powell; D Sims; C Thornton
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-01       Impact factor: 5.747

8.  Application of pulsed field gel electrophoresis to the 1993 epidemic of whooping cough in the UK.

Authors:  S N Syedabubakar; R C Matthews; N W Preston; D Owen; V Hillier
Journal:  Epidemiol Infect       Date:  1995-08       Impact factor: 2.451

9.  Serum antibodies to the components of diphtheria-tetanus-pertussis vaccine in Polish children related to vaccination status.

Authors:  E Torbicka; T Lagergård; B Trollfors
Journal:  Infection       Date:  1995 Jul-Aug       Impact factor: 3.553

10.  Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease.

Authors:  Van C Willis; M Kristen Demoruelle; Lezlie A Derber; Catherine J Chartier-Logan; Mark C Parish; Isabel F Pedraza; Michael H Weisman; Jill M Norris; V Michael Holers; Kevin D Deane
Journal:  Arthritis Rheum       Date:  2013-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.